Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Lntervertebral Local Administration of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Lnterbody Fusion

NCT06115512 is registered in ClinicalTrials.gov with Angitia Biopharmaceuticals as lead sponsor.

NCT NCT06115512
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06115512 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Lntervertebral Local Administration of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Lnterbody Fusion
Lead sponsor
Angitia Biopharmaceuticals
Phase
Phase 3
Overall status
Terminated
Start date
December 8, 2023
Completion date
June 12, 2026
Enrollment
412 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

degenerative disc disease